New inhaler for COPD shows promise in early trial
NCT ID NCT06035393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental inhaled drug called HRG2005 in people with moderate to severe chronic obstructive pulmonary disease (COPD). The goal was to see if it improves lung function compared to a standard treatment. About 82 participants were enrolled, but the study was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRG2005 inhalation
- What this could lead to
- If successful, this could point toward a new inhaled treatment option for people with moderate to severe COPD.
- What could go wrong
- The trial was terminated early, so results are limited. It is a Phase 2 study, meaning it is still early and may not lead to a proven treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD